{"id":"W4405009230","doi":"10.1016/s2352-3026(24)00319-3","title":"Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Agios Pharmaceuticals","keywords":"Medicine; Placebo; Clinical trial; Internal medicine; Double blind; Physical therapy; Pediatrics; Intensive care medicine; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009600186,0.000174014,0.001325687,0.00004489508,0.00004910631,0.00001091796,0.0001596724,0.0001569633,0.00003869324],"category_scores_gemma":[0.0005394723,0.00008693995,0.0001991833,0.0002680795,0.0003126311,0.00003368109,0.00005543176,0.0002888437,0.000008611372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002601383,"about_ca_system_score_gemma":0.0001978513,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002667051,"about_ca_topic_score_gemma":0.00005350687,"domain_scores_codex":[0.9980592,0.0003239166,0.0008969344,0.0002800997,0.000185299,0.0002545707],"domain_scores_gemma":[0.997653,0.001488077,0.0002561712,0.0004724866,0.000042554,0.00008769125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9940813,0.0004474635,0.0002372421,0.0001630213,0.0001742917,0.0001789596,0.0009923797,0.00005589139,0.0001329536,0.0008960635,0.00194058,0.0006999185],"study_design_scores_gemma":[0.9948518,0.0002673873,0.0002544054,0.0002370278,0.0007824817,0.00003872274,0.0003335441,0.00145403,0.0001732836,0.0005715199,0.0009483025,0.00008749452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9703677,0.01094256,0.00004667024,0.0127284,0.000465925,0.003872132,0.000158021,0.00003741145,0.001381195],"genre_scores_gemma":[0.9978126,0.001607398,0.00001777773,0.0001509009,0.0001533921,0.00006931392,0.00007205035,0.00001269475,0.0001038773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02744491,"threshold_uncertainty_score":0.3545308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02336994305136065,"score_gpt":0.3126086637001989,"score_spread":0.2892387206488383,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}